ThyroSeq® International

Molecular test for cytologically indeterminate thyroid nodules empowering individualized patient management

- Cutting-edge next-generation sequencing technology
- Most rigorously validated test on the market
- Reliable detection of all types of thyroid tumors
- Highest reduction in number of diagnostic surgeries
- Reports comprehensive detailed molecular profile with cancer risk assessment
- Every test reported by licensed physician





contacto@atecsa.mx

ThyroSeq® International

Molecular test for cytologically indeterminate thyroid nodules empowering individualized patient management

LEADING PLATFORM FOR COMPREHENSIVE GENOTYPING OF THYROID NODULES

ThyroSeq interrogates 112 genes across 5 classes of genomic alterations, providing information on >12,000 mutation hotspots and >150 gene fusion types.

MOST RIGOROUSLY VALIDATED TEST ON THE MARKET

ThyroSeq was validated in the largest, prospective, double-blind, multicenter study (Steward et al. *JAMA Oncol*. 2019.) of any commercially available molecular test for indeterminate thyroid nodules.[1]

HIGHEST NPV AND PPV AMONG WELL-VALIDATED TESTS

ThyroSeq has the highest negative predictive value at 97% (rule-out) and positive predictive value (rule-in) at 64% among well-validated tests for thyroid nodules.[1]

HIGHEST REDUCTION IN DIAGNOSTIC SURGERIES

ThyroSeq allows for avoidance of diagnostic surgery in up to 61% of patients with indeterminate nodules, and up to 82% of all benign nodules with indeterminate cytology.[1] Most cost-effective test on the market.[5]

COMPREHENSIVE TUMOR PROFILING WITH CANCER RISK ASSESSMENT

ThyroSeq tests all main types of genetic alterations, providing patient-specific probability of cancer and prediction of risk of cancer recurrence, allowing physicians to individualize patient management.

RELIABLE DETECTION OF HCC, MTC, PARATHYROID, AND METS

ThyroSeq has demonstrated reliable detection of Hurthle cell cancer, medullary thyroid cancer, and non-thyroidal tumors.[1,2,3,4]

EMPOWERING INDIVIDUALIZED PATIENT MANAGEMENT



MTC-medullary thyroid carcinoma, LR-low risk, HR-high risk, CNA-copy number alterations, GEA-gene expression alterations, LND-lymph node dissection

References: 1. Steward DL, et al. *JAMA Oncol* 2019. 2. Nikiforova MN, et al. *Cancer*. 2018. 3. Schatz-Siemers N, et al. *Diagn Cytopathol.* 2019. 4. Cho M, et al. *Cancer Cytopathol*. 2017. 5. Nicholson KJ, et al. *Thyroid*. 2019.

contacto@atecsa.mx